Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best strong buy healthcare stocks to invest in. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its fiscal Q4 and full-year 2025 earnings on February 25, reporting that total revenue for the year ended December 31, 2025, was $944 million compared to $705 in the previous year, considerably surpassing expectations due to continued commercial success. The company also earned substantial R&D revenue, including a $280 million upfront payment for the global license of sapablursen to Ono Pharmaceutical Co., Ltd. in fiscal Q2 2025. Total revenue for Q4 was $203 million, compared to $227 million in the prior year period.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) further reported that operating expenses for the full year were in line with expectations and rose year over year from investments related to commercialization efforts for TRYNGOLZA, DAWNZERA, and WAINUA. Following the rating update, Needham lifted the price target on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to $103 from $90 on February 25, maintaining a Buy rating on the shares and telling investors that it sees upside to the company’s 2026 revenue outlook as the year progresses.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) develops and commercializes human therapeutic drugs using antisense technology. It functions through the Ionis Core segment, which generates a pipeline of drugs through a novel drug discovery platform.